TABLE 1.
Patient characteristics before budesonide therapy and the response to its use
| Age, years | Autoantibodies | Pretreatment liver biopsy, grade/stage | Prebudesonide prednisone dose, mg/day | Postbudesonide prednisone dose, mg/day | Response | Duration of therapy, months |
|---|---|---|---|---|---|---|
| 24 | ASMA 1:1280 | 1/3 | 0 | 0 | CR | 15 |
| 42 | ASMA 1:40 | 2/1 | 15 | 0 | CR | 28 |
| 12 | ANA 1:160 | – | 0 | 0 | CR | 9 |
| 17 | ASMA 1:80 | 1/0 | 10 | 0 | CR | 96 |
| 66 | ANA 1:512 | – | 15 | 15 | NR | 6 |
| 49 | ASMA 1:80 | 2/1 | 0 | 0 | CR | 6 |
| 61 | ANA 1:80 | – | 10 | 10 | NR | 15 |
| 43 | ASMA 1:160 | 1/2 | 15 | 0 | CR | 30 |
| 34 | ANA 1:320 | – | 15 | 0 | CR | 24 |
ANA Antinuclear antibody titre; ASMA Anti-smooth muscle antibody titre; CR Complete response (sustained normalization of aspartate aminotransferase and alanine aminotransferase levels); NR No response (Reduction of aspartate aminotransferase and alanine aminotransferase levels of less than 50%)